Search
Publications & Presentations * Presentations * 2000-2005
Presentations 2000-2005
2005

10th European AIDS Conference/EACS, Dublin, November 2005


Posters

1 Liver-related Deaths among HIV-infected Persons; Data from the D:A:D Study.
R Weber, N Friis-Møller, CA Sabin, P Reiss, A D’Arminio Monforte, F Dabis, W El-Sadr, S De Wit, L Morfeldt, MG Law, C Pradier, G Calvo, O Kirk, AN Phillips, JD Lundgren o­n behalf of the D:A:D study group.
Poster PE18.4/7

2 Comparison of resistance profiles between patients starting nevirapine and efavirenz in EuroSIDA. W Bannister, L Ruiz, B Ledergerber, A Cozzi-Lepri, O Kirk, S Staszewski, C Loveday, B Clotet, A Phillips, J Lundgren for the EuroSIDA study group. Poster PE17.5/2

3 Evolution of drug resistance in HIV infected patients remaining o­n a virologically failing cART regimen. A Cozzi-Lepri, AN Phillips, L Ruiz, B Clotet, C Loveday, J Kjaer, N Clumeck, L Viksna, F Antunes, L Machala and JD Lundgren.  Poster PE17.4/2

4 Pilot of the CoDe (Coding of Death) project - a standardized approach to code causes of death in HIV infected individuals. CH Olsen, N Friis-Møller, A d'Arminio Monforte, G Chene, R Davey, S De Wit, F De Wolf, M Egger, M Ellefson,W El-Sadr, O Kirk, M Law, B Ledergerber, C Lewden, S Mateu, A Mocroft, T Peto, A Phillips, C Pradier, P Reiss,  F Rhame, C Sabin, J Sterne, R Weber, B Åkerlund, JD Lundgren, for the CoDe Working Group. Poster PE18.4/9

Oral presentations

1 Use of antimycotic therapy is an independent risk factor for HIV-disease progression among patients with a CD4 count above 200/µL in the era of combination antiretroviral therapy .
D Podlekareva, A Mocroft, P Reiss, P Aldins, C Katlama, B Ledergerber, HJ Stellbrink, AD Monforte, O Kirk, JD Lundgren Abstract PS 2/1

2 Is there an association between the endpoints in trials of virological efficacy and clinical long-term prognosis? O Kirk, A Mocroft, P Reiss, B Ledergerber, B Knysz, G Fätkenheuer, S Chaplinskas, JM Gatell, A Phillips, JD Lundgren for the EuroSIDA Study Group Abstract PS 3/4

3 Clinical progression according to HIV drug resistance accumulated o­n antiretroviral therapy in EuroSIDA. A Cozzi-Lepri, A Phillips, A Mocroft, O Kirk, L Ruiz and JD Lundgren. Abstract PS 6/4

4 Is there evidence for an increase in the death rate from liver-related diseade in patients with HIV? The EuroSIDA study. JD Lundgren, A Mocroft, V Soriano, J ROchstroh, P Reiss, O Kirk, S de Wit, JM Gatell, B Clotet, A Phillips Abstract PS 7/2

3rd IAS Conference o­n HIV Pathogensis and Treatment, Rio de Janeiro, July 2005

1 Rates of viral suppression and regimen change according to initial HAAR regimen. A collaborative analysis of 12 prospective cohort studies.
R Hogg, J Lundgren, D Costagliola, A d´Arminio Monforte, B Ledergerber, F de Wolf, G Fusco, S Staszewski, G Chene, A Phillips, J Gil, N Schmeisser, M May, J Sterne, M Egger.

2 Impact of Lamivudine (3TC) o­n the risk of liver related death (LRD) in 2,041 HBsAg and HIV-positive inidividuals. Results of an intercohort analysis. M Puoti, A Cozzi-Lepri, G Parainfo, J Lundgren, M Rickenback, I Suarez-Lozano, M Winnock, A Gervais, J Gill, J Rockstroh, C Mussini, A Castagna, A De Luca, A d´Arminio Monforte.

3 Risk factors for new o­nset diabetes mellitus (DM) in HIV patients. C Sabin, N Friis-Møller, P Reiss, R Weber, A d´Arminio Monforte, F Dabis, W El-Sadr, S de Wit, S Mateu, O Kirk, C Pradier, L Morfeldt, M Law, J Lundgren.

3rd European Resistance Conference, Athens, March 2005

1 The COLATE trial: comparison of the evolutionary distance for protease and reverse transcriptase sequences.
J Kjær Poster(352 KB) abstract 

2 How to read viral load in patients with virus variants that you can not suppress.
J Lundgren

12th Conference o­n Retroviruses and Opportunistic Infections, Boston, February 2005

1 Cardiovascular outcomes in HIV infection.
JD Lundgren et al

2 Changes over time in antiretroviral therapy (ART) use and risk factors for cardiovascular disease (CVD) in the D:A:D study.
C Sabin, L Morfeldt, N Friis-Møller, M Rickenbach, P Reiss, A D´Arminio Monforte, C Pradier, O Kirk, G Calvo, M Law, P Mercié,  W El-Sadr, S De Wit, JD Lundgren o­n behalf of the D:A:D study group. Poster # 866(70 KB)

3 Relationship between prolonges exposure to combination antiretroviral therapy (cART) and myocardial infarction (MI): effect of sex, age and lipid changes. W El-Sadr, P Reiss, S De Wit, A D´Armino Monforte, R Thiebaut, L Morfeldt, R Weber, C Pradier, G Calvo, MG Law, O Kirk, C Sabin, N Friis-Møller JD Lundgren o­n behalf of the D:A:D study group.

4 HIV and Non-HIV-related deaths and their relationship to immunodeficiency; the D:A:D study. R Weber, N Friis-Møller, C Sabin, P Reiss, A D´Arminio Monforte, F Dabis, W El-Sadr, S De Wit, L Morfeldt, MG Law, C Pradier, G Calvo, C Holkmann Olsen, AN Phillips, JD Lundgren o­n behalf of the D:A:D study group. Poster #595 (75 KB)

5 Risk of AIDS and death at given HIV-RNA and CD4 count level, according to specific antiretroviral drugs in the CART regimen. C Holkmann-Olsen1, J Gatell, B Ledergerber, C Katlama, N Friis-Møller, J Weber, A Horban, S Staszewski, J Lundgren, A Phillips, and EuroSIDA
Poster #601(78 KB)

6 HIV-1 subtypes and virological response to HAART in Europe. W Bannister, L Ruiz, C Loveday, S Vella, K Zilmer, D Podlekareva, B Knysz, A Phillips, J Lundgren, A Mocroft and the EuroSIDA study group  Poster #598(157 KB)

7 Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact o­n virological response to therapy. A Cozzi-Lepri, L Ruiz, C Loveday, A Phillips, B Clotet, P Reiss, J Lundgren, and EuroSIDA Study Group Poster #708(113 KB)

8 A Comparison of Risk of Treatment Limiting Adverse Events in HCV-co-infected vs Non-co-infected persons with HIV in EuroSIDA. JD Lundgren, J Rockstroh, V Soriano, B Ledergerber, O Kirk, E Vinogradova, P Reiss, C Katlama, A Blaxhult, A Mocroft, and EuroSIDA Study Group
Poster #946(137 KB)

9 Mortality Rates According to Initial HAART Regimen: A Collaborative Analysis of 12 Prospective Cohort Studies. R Hogg, J Lundgren, D Costagliola, A Monforte, B Ledergerber, F de Wolf, G Fusco, S Staszewski, G Chêne, A Phillips, J Gill, J Rockstroh, M May, J Sterne, M Egger, and ART Cohort Collaboration

2004

11th Conference o­n Retroviruses and Opportunistic Infections, San Francisco, February 2004

1 Predictors of Hypertension and Changes in Blood Pressure in HIV-infected Patients in the D:A:D study. R Thiebaut, W El-Sadr, N Friis-Møller, M Rickenbach, P Reiss, A D´Arminio Monforte, L Morfeldt, C Pardier, O Kirk, S De Wit, G Calvo, M Law, C Sabin, J D Lundgren and D:A:D Study Group. (DAD 75)

2 Final Week 48 Analysis of a Phase 4, Randomised, Open-label, Multi-center Trial to Evaluate Safety and Efficacy of Continued Lamivudine Twice Daily Versus Discontinuation of Lamivudine in HIV-1-infected Adults with Virological Failure o­n o­ngoing Combination Treatments Containing Lamivudine: The COLATE Trial. U Dragsted, Z Fox, L Mathiesen, C Katlama, M Youle, J Gerstoft, J N Bruun and J D Lundgren for the COLATE Trial Group  (COLATE 549)

3 Time to Triple Drug Class Failure after Initiation of HAART. A Mocroft, B Ledergerber, J P Viard, S Staszewski, M Murphy, A Chiesi, A Horban, A B Hansen, A N Phillps, J D Lundgren and the EuroSIDA Study Group. (EuroSIDA 554)

4 The Role of Genetic Polymorphisms of the MDR1 Gene in the MaxCmin1 Study. A Owen, Z Fox, L Almond, U Bak Dragsted, D Back, M Youle, J Lundgren, S Khoo, and the MaxCmin1 Steering Commitee. (MaxCmin1 619b)

5 Lipid Profiles of Patients Enrolled in the MaxCmin2 Trial: A Randomised, Open-label Multi-centre Comparative Trial Evaluating the Safety and Efficacy of Lopinavir/ Ritonavir (400/100 mg twice daily) vs Saquinavir/Ritonavir SQV/r (1000/100 mg twice daily). S L Walmsley, J Benetucci, A Brutus, N Clumeck, U B Dragsted, B Gazzard, N Obel, P Vernazza, Z Fox, J D Lundgren and o­n behalf of the MaxCmin2 Trial Group. (MaxCmin2 720)

6 Cardio- and Cerebrovascular Events and Predicted Rates of Myocardial Infarction in the D:A:D study. M G Law, A D´Arminio Monforte, N Friis-Møller, R Weber, W El-Sadr, P Reiss, F Dabis, L Morfledt, S De Wit, C Pradier, G Calvo, O Kirk, C Sabin, A N Phillips and JD Lundgren. (DAD 737)

7 Hepatitis B and Hepatitis C in the EuroSIDA Cohort: Prevalence and Effect o­n Mortality, AIDS Progression and Response to HAART. J Rockstroh, D Konopnicki, V Soriano, O Kirk, F Antunes, B Knysz, C Tural, S De Wit, A Mocroft, J Lundgren and the EuroSIDA Study Group.
(EuroSIDA 799)

XV International AIDS Conference, July 2004, Bangkok

1 Estimation of clinical events in the control arm of the ESPRIT trial based o­n data from an observational database. J D Lundgren
(ESPRIT B10257) abstract

2 Predictors of the CD4 count response during the first 8 months of follow-up in the IL-2 arm of ESPRIT. K Ruxrungtham, Z V Fox, F Antunes, J D Bebchuk, R T Davey, B Gazzard, N G Klimas, A M Labriola, M H Losso, J D Neaton, S Staszewski, L Weiss, A N Phillips, J D Lundgren.
(ESPRIT WeOrB1288) abstract

3 Comparison of observed clinical event rates in the ESPRIT trial with projections from the EuroSIDA study. J D Lundgren, A Mocroft, J Bebchuck, S. Staszewski, F Antunes, B Knysz, M Law, A N Phillips, J Neaton.
(ESPRIT/EuroSIDA WePeB5685) abstract

44th ICAAC, October 2004, Washington

1 Comparison of 6 HIV-1 genotypic resistance algorithms for predicting viral load change to week 4.
Z Fox, J Gerstoft, UB Dragsted, AN Phillips, P Cahn, J Gatell, JD Lundgren (MaxCmin2 H-185)

6th International Conference o­n Adverse Drug Reactions and Lipodystrophy in HIV, October 2004, Washington

1 Association of risk toxicity with drug levels of saquinavir boosted with ritonavir in the MaxCmin 1 & 2 trials. JD Lundgren, Z Fox, US Justesen, S Warmsley, M Youle, P Vernazza, J Gerstoft, M Losso, and UB Dragsted o­n behalf of the MaxCmin trial groups. (MaxCmin 1&2 79)

2 Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen. A Mocroft, AN Phillips, V Soriano, J Rockstroh, A Blaxhult, C Katlama, A Boron-Kaczmarska, L Viksna, O Kirk, JD Lundgren for the EuroSIDA study group. (EuroSIDA 74)

7th International Congress o­n Drug Therapy in HIV Infection, November 2004 Glasgow

1 Interruption/stopping HAART and risk of clinical disease progression to AIDS/death in EuroSIDA.
C Holkmann-Olsen, A Mocroft, S Vella, A Blaxhult, N Clumeck, O Kirk, M Fisher, C Katlama, A Phillips, J Lundgren (EuroSIDA P5) abstract

2 What is the status of IL-2? J D Lundgren. (PL8.1)

3 Why do patients stop antiretrovirals used as part of an initial HAART regimen? Results from the EuroSIDA study group. A Mocroft, A Phillips, V Soriano, J Rockstroh, A Blaxhult, C Katlama, A Boron-Kaczmarska, L Viksna, O Kirk, J Lundgren (EuroSIDA PL14.1)

4 HIV-patients across Europe: regional differences in patient characteristics. D Podlekareva, W Bannister, L Viksna, A Mocroft, B Knysz, P Reiss, N Chentsova, D Duiculescu, JD Lundgren, O Kirk, The EuroSIDA Study. (EuroSIDA P67)

2003

10th Conference o­n Retroviruses and Opportunistic Infections, Boston, February 2003

1. Exposure to HAART is associated with an increased risk of myocardial infarction: The DAD study. N Friis-Møller, R Weber, A D´Arminio Monforte, W El-Sadr, P Reiss, F Dabis, L Morfeldt, S De Wit, C Pradier, G Calvo, M Law, O Kirk, C Sabin, JD Lundgren. (DAD 130)

2. Factors affecting CD4 count slope in patients with stable viral load following three class virologic failure: The PLATO collaboration. B Ledergerber, JD Lundgren, G Fusco, R Weber, F Wit, F Castelli, S Staszewski, R Hogg, AS Walker, K Petoumenos, A D´Armenio Monforte, C Mussioni, F Lampe, MJ Gill, A Phillips.  (PLATO 146lb)

3. Changes in AIDS, death Rates and survival after AIDS in the EuroSIDA study: 1994-2002. A Mocroft, B Ledergerber, C Katlama, O Kirk, P Reiss, A D´Arminio-Monforte, B Knysz, M Dietrich, AN Phillips, JD Lundgren.  (EuroSIDA 180)

4. Does it matter where you came from? Prognosis of patients starting potent therapy, according to initial response. JAC. Sterne, M May, D Costagliola, P Pezzotti, B Ledergerber, F de Wolf, J Lundgren, JS Fusco, S Staszewski, F Raffi, RS Hogg, AN Phillips, MJ Gill, G Faetkenheuer, G Chene.  (Art Cohort 181)

5. The changing incidence of clinical AIDS events in 12,574 treatment-naïve patients starting HAART. C Sabin, A D´Arminio Monforte, M May, S Grabar, P Reiss, J Lundgren, A Justice, S Staszewski, C Leport, F Dabis, JSG Montaner, M Johnson, J Gill, G Faetkenheuer, M Egger.  (Art Cohort 569)

British HIV Association Conference, Manchester, April 2003

1. ART and myocardial infarction: how to deal with the incertainty.
JD Lundgren

2nd International AIDS Society Conference, Paris, July 2003

1. Factors contributing to the success of ART following three class virological failure: The PLATO collaboration.
B Ledergerber, JD Lundgren, GP Fusco, R Weber, F Wit, F Castelli, S Staszewski, R Hogg, AS Walker, K Petoumenos, A d´Arminio Monforte, C Mussini, F Lampe, MJ Gill and AN Phillips. (Plato 576)

2. Presence of GB virus C and response to HAART, analysed within the MaxCmin1 trial comparing the efficacy and safety of indinavir/ritonavir versus saquinavir/ritonavir. HL Tilmann, T Kaiser, Z Fox, S Staszewski, F Antunes, A d´Arminio Monforte, A Telenti, UB Dragsted and JD Lundgren o­n behalf of the MaxCmin Trial Group. (MaxCmin 1006)

3. The final Week 48 analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid): The MaxCmin2 trial. M Youle, J Gerstoft, Z Fox, M Losso, DT Jayweera, A Rieger, JN Bruun, A Castagna, S Walmsley, A Hill, UB Dragsted and JD Lundgren for the MaxCmin2 Trial Group.
(MaxCmin2 LB23)


5th International Conference o­n Adverse Drug Reactions and Lipodystrophy in HIV, Paris, July 2003.

1. Safety o­n NNRTI therapy. Data from the EuroSIDA study. N Friis-Møller, O Kirk, P Reiss, A Mocroft, C Katlama, A Horban, D Banhegyi, J Gatell, B Clotet, AN Phillips and JD Lundgren for the EuroSIDA Study Group. (EuroSIDA 24)

2. Hepatotoxicity of ritonavir-boosted indinavir (IDV/r 800/100 mg twice daily) and saquinavir (SAQ/r 1000/100 mg twice daily) in a phase IV, randomised, open-label and multi centre trial in adult HIV-1 infection: MaxCmin1 trial. JD Lundgren, A Hill, Z Fox, N Clumeck, JN Bruun, J Bennetucci, I Cassetti, P Vernazza, A Rieger and UB Dragsted o­n behalf of the MaxCmin1 trial. (MaxCmin1 126)

43nd ICAAC, Chicago, September 2003

1. Risk of death following triple class virological failure: The PLATO Collaboration.
JD Lundgren, B Ledergerber, GP Fusco, R Weber, P Reiss, F Castelli, S Staszewski, R Hogg, AS Walker, K Petoumenos, A D´Arminio Monforte, C Mussini, F Lampe, MJ Gill, AN Phillips.

9th EACS, Warsaw, October 2003

1. Pharmacokinetics from a 48-week randomised trial to evaluate safety and efficacy of indinavir/ritonavir 800/100 mg versus saquinavir/ritonavir 1000/100 mg: The MaxCmin1 trial. U Justesen, Z Fox, C Pedersen, P Cahn, J Gerstoft, N Clumeck, A Duran, B Peters, N Obel, A Castagna, U Dragsted, J Lundgren o­n behalf of the MaxCmin1 trial group. (MaxCmin 1 F2/5)

2. Virologic outcome of patients with virologic failure who start a regimen containing Abacavir: EuroSIDA Study. C Cabrera, A Cozzi-Lepri, AN Phillips, C Loveday, T Puig, O Kirk, M Ait-Khaled, B Ledergerber, J Lundgren, B Clotet, L Ruiz.  (EuroSIDA F6/5)

3. Prevalence of lipodystrophy and retinoid syndrome in a 48-week randomised trial to evaluate safety and efficacy of indinavir/ritonavir 800/100 mg versus saquinavir/ritonavir 1000/100 mg: The MaxCmin1 trial. S De Wit, H Wand, M Law, A Castagna, JN Bruun, M Youle, P Vernazza, I Cassetti, J Benetucci, U Dragsted, JD Lundgren o­n behalf of the MaxCmin1 trial group.  (MaxCmin 1 F8/2)

4. Hepatitis B (HBV) in the EuroSIDA Cohort: prevalence and impact o­n mortality, AIDS progression and response to HAART. D Konopnicki, S De Wit, F Antunes, B Ledergerber, C Katlama, K Zilmer, O Kirk, S Vella, A Mocroft and JD Lundgren for the EuroSIDA Group.
(EuroSIDA F9/3)

5. Changing incidence of central nervous system (CNS) AIDS-related diseases in the EuroSIDA cohort. A d'Arminio Monforte, P Cinque, A Mocroft, FD Goebel, F Antunes, C Katlama, US Justesen, S Vella, O Kirk, JD Lundgren for the EuroSida Study Group. (EuroSIDA F9/6)

6. Changes in hospital admissions across Europe in 1995-2002. A D’Arminio Monforte, A Mocroft, O Kirk, MA Johnson, N Friis-Moller, D Banhegyi, A Blaxhult, F Mulcahy, JM Gatell, JD Lundgren for the EuroSIDA study group.  (EuroSIDA F9/7)

7. The final Week 48 analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid): The MaxCmin2 trial. M Youle, J Gerstoft, Z Fox, M Losso, DT Jayweera, A Rieger, JN Bruun, A Castagna, S Walmsley, A Hill, UB Dragsted, JD Lundgren for the MaxCmin2 trial group.  (MaxCmin2 F11/3)

8. Influence of Hepatitis C coinfection o­n HIV disease progression within the EuroSIDA Cohort. J Rockstroh, A Mocroft, V Soriano, C Tural, M Losso, P Reiss, L Machala, O Kirk, B Ledergerber, JD Lundgren for the EuroSIDA study group. (EuroSIDA F12/4)

9. Regional differences in characteristics of HIV-patients from across Europe The EuroSIDA study. LViksna, A Mocroft, B Knysz, JP Viard, M Dietrich, D Duiculescu, A Blaxhult, F Antunes, JD Lundgren, O Kirk for the EuroSIDA Study Group.  (EuroSIDA 18.2/2)

10. Use of and response to antiretroviral therapy in regions of Europe The EuroSIDA Study. A Horban, A Mocroft, B Ledergerber, A Johnson, S Chaplinskas, JM Gatell, A Chiesi, AN Phillips, JD Lundgren, O Kirk for the EuroSIDA study group. (EuroSIDA 18.2/3)

2002

9th Conference o­n Retroviruses and opportunistic Infections in Seattle, February 2002

1. Interruption/Stopping Antiretroviral Therapy and the Risk of Clinical Diseases: Results from the EuroSIDA Study. JD Lundgren, S Vella, L Paddam, A Blaxhult, N Vetter, N Clumeck, G Panos, M Fisher, C Katlama, and AN Phillips.  (EuroSIDA 48)

2. Safe Interruption of Maintenance Therapy (MT) against Prior Infection with 4 Common HIV-Associated Opportunistic Pathogens during Highly Active Antiretroviral Therapy. O Kirk, P Reiss, C Uberti-Foppa, M Bickel, J Gerstoft, C Pradier, F Wit, B Ledergerber, JD Lundgren, and H Furrer for 7 European HIV cohorts.  (EuroSIDA 37)

3. Analysis of Virological Efficacy in Randomised Trials of Antiretroviral Regimens: Drawbacks of No HIV-RNA Measurements after Premature Interruption of Therapy. O Kirk, M Law, C Pedersen. RM Gulick, G Moyle, AN Phillips, and JD Lundgren. (EuroSIDA Abstract G104e, Poster 551-T)

4. Distinguishable Lipid Profiles between PI and NNRTI Therapy May Carry Different Risk of CardiovascularDisease (CVD). F van Leth, N Friis-Møller, R Weber, A d'Arminio Monforte, O Kirk, R Thiebaut, L Morfeldt, C Pradier, G Calvo, M Law, G Bartsch, S De Wit, C Sabin, JD Lundgren, P Reiss for the D:A:D Study Group.  (DAD 34)

5. The Interim Analysis of a Phase IV Randomised, Open-Label, Multicentre Trial to Evaluate Safety and Efficacy of Indinavir/Ritonavir (800/100 mg bid) vs. Saquinavir/Ritonavir (1000/100 mg bid) in Adult HIV-1 Infection: The MaxCmin1 Trial. A Castagna, UB Dragsted, J-P Chave, A Rieger, G Carosi, S van der Geest, H Nielsen, and JD Lundgren o­n behalf of the MaxCmin1 trial group.
(MaxCmin G1008e)


British HIV Association Conference, York, April 2002

1. Current status of patients starting HAART during 1996: descriptive analysis of EuroSIDA participants. Lucy Paddam, O Kirk, JM Gatell, P Reiss, F Antunes, AM Johnson, A Horban, C Pradier, B Ledergerber, AN Phillips, and JD Lundgren o­n behalf of The EuroSIDA Study Group.
(EuroSIDA)


The 14th International AIDS Conference, Barcelona, July 2002

1. Modelling Risk of Cardiovascular Events in HIV. M Law, N. Friis-Møller, R Weber, P Reiss, A d'Arminio Monforte, O Kirk, R Thiebaut, C Pradier, L Morfeldt, G Calvo, G Bartsch, S De Witt, C Sabin, JD Lundgren for the D:A:D Study Group.  (DAD WePeC6260)

2. Virological, immunological and clinical response to highly active antiretroviral therapy: the gender issue revisited. AL Moore, O Kirk, JD Lundgren, AN Phillips  (EuroSIDA B10508)

3. Week 48 data of a randomised trial to evaluate safety and efficacy of indinavir/ritonavir (800/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid) in adult HIV-1 infection. P Cahn, UB Dragsted, C Pedersen, B Peters, A Duran, N Obel, JM Gatell, C Leen, J v Lunzen, A Stoehr, J Lederman, and JD Lundgren o­n behalf of the MaxCmin1 trial group.  (MaxCmin WeOrB1265)

4. A randomised trial comparing HAART regimens of Nelfinavir/Nevirapine and Ritonavir/Saquinavir in PI and NNRTI naïve patients. O Kirk, JD Lundgren, C Pedersen, L Mathiesen, H Nielsen, T Katzenstein, N Obel, J Gerstoft.  (DAPIS TuOrB1188)

5. What is the prognostic value of baseline CD4 cell count and viral load six months after initiating potent antiretroviral therapy? ART Cohort Collaboration. JAC Sterne, S Grabar, A d’Arminio Monforte, M Rickenbach, F de Wolf, JD Lundgren, J Fusco, V Miller, F Raffi, F Dabis, RS Hogg, F Lampe, MJ Gill, B salzberger, M May, M Egger.  (ART Cohort C10680)

6. Prognosis of HIV-1 infected drug naïve patients starting potent antiretroviral therapy. ART Cohort Collaboration. G Chene, M May, D Costagliola, A d’Arminio Monforte, C Junghans, F de Wolf, JD Lundgren, G Fusco, V Miller, C Leport, F Dabis, RS Hogg, AN Phillips, MH Gill, B Salzberger, JAC Sterne, M Egger.  (ART Cohort TuOrB1140)

7. Construction and validation of a prognostic model for progression to AIDS or death in drug-naïve patients starting potent antiretroviral therapy ART Cohort Collaboration. M May, JAC Sterne, D Costagliola, P Pezzotti, B Ledergerber, F de Wolf, JD Lundgren, AC Justice, V Miller, G Chene, F Cabid, RS Hogg, C Sabin, MJ Gill, B Salzberger, M Egger.  (ART Cohort TuPeB4668)


42nd Interscience Conference o­n Antimicrobial Agents and Chemotherapy, San Diego, December 2002


1. Final Analysis of a Randomised Trial to Evaluate Safety and Efficacy of Indinavir/Ritonavir versus Saquinavir/Ritonavir in Adult HIV-1 Infection: The MaxCmin1 Trial.
J Gerstoft, UB Dragsted, P Cahn, A Castagna, A Duran, A Hill, C Pedersen, B Peters, P Vernazza, M Youle, and JD Lundgren o­n behalf of the MaxCmin1 trial group.  (MaxCmin ICAAC02-A-2853-ASM)

2. Abacavir, Didanosine and Stavudine versus Ritonavir, Saquinavir, Zidovudine and Lamivudine or Nelfinavir, Nevirapine, Zidovudine and Lamivudine in Antiretroviral Naïve HIV Patients. J Gerstoft, O Kirk, N Obel, H Nielsen, L Mathiesen, C Pedersen, J Lundgren.

3. The Evolution of HIV in Patients with Insufficient Viral Suppression during HAART. TB Kristiansen, AG Pedersen, J Eugen-Olsen, T Katzenstein, JD Lundgren.

6th Congress o­n Drug Therapy in HIV Infection, Glasgow, November 2002

1. Lipid profiles o­n therapy with PI. The D:A:D Study. C Pradier, C Sabin, N Friis-Møller, R Weber, P Reiss, A d'Arminio Monforte, O Kirk, R Thiebaut, E Fontas, L Morfeldt , G Calvo, M Law, G Bartsch, S De Witt, JD Lundgren for the DAD Study Group.  (DAD PL21.1)

2. Virological rebound after suppression o­n HAART: result from the EuroSIDA study. A Mocroft, A Phillips, P Reiss, B Clotet, B Ledergerber, J Gatell, C Katlama, S Vella, N Clumeck, JD Lundgren  (EuroSIDA PL5.4)

3. The interim analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of Lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid) in adult HIV-1 infection: The MaxCmin2 trial. UB Dragsted, J Gerstoft, M Youle, A Duran, DT Jayaweera, A Rieger, JN Bruun, A Castagna, S Walmsley, Z Fox, A Hill, and JD Lundgren for the MaxCmin2 trial group. (MaxCmin2 PL14.5)

4. Final Safety and Efficacy Analysis of a Randomised Trial Evaluating Indinavir/Ritonavir versus Saquinavir/Ritonavir in Adult HIV-1 Infection: The MaxCmin1 Trial. J Gerstoft, U Bak Dragsted, P Cahn, A Castagna, A Duran, A Hill, C Pedersen, B Peters, P Vernazza, M Youle, and JD Lundgren o­n behalf of the MaxCmin1 trial group. (MaxCmin P29)

4th European Conference o­n the Methods and Results of Social and Behavioural Research o­n AIDS, September 2002, Vilnius.

1. The EuroSIDA Study 1994-2002
. O Kirk, o­n behalf of the EuroSIDA study Group.

2001

The Australian ASHM Conference, Melbourne, 2001

1. Cardiovascluar risk in Hiv patients - association with antiretroviral therapy. The DAD Study.
M Law, N Friis-møller, P Reiss, A d´Arminio Monforte, M Rickenbach, R Thiebaut, C Pradier, L Morfeldt, G Calvo, G Bartsch, S De Wit, AN Phillips, JD Lundgren for the DAD study group.

8th Conference o­n retroviruses and opportunistic infections, Chicago, February 2001

1. Changes in cause of death across Europe. A Mocroft, R Brettle, O Kirk, A Blaxhult, JM Parkin, F Antunes, P Francioli, A d´Arminio Monforte, AN Phillips, and JD Lundgren. (EuroSIDA 298)

2. Virological and clinical outcome of NNRTI-containing regimens for 1932 patients in EuroSIDA. AN Phillips, C Pradier, A Lazzarin, B Clotet, F Goebel, P Hermans, F Antunes, B Ledergerber, O Kirk, and J Lundgren. (EuroSIDA 324)


5th International Workshop o­n HIV observational databases, Monte Carlo, April 2001

1. The influence of the analytic method used in clinical trial of HAART. Results form EuroSida and randomised clinical trials (RCT). O Kirk and J Lundgren. (EuroSIDA oral ses. 2)

2. Predictors of clinical outcome – how different are they form predictors of virological outcome? JD Lundgren  (EuroSIDA oral ses 3)

3. The DAD-study: Data collection o­n adverse events of anti-HIV drugs. DAD study group  (DAD oral ses.6)

4. Changes in viral load in people with virological failure who remain o­n the same HAART regimen. A Cozzi-Lepri, A Phillips, V Miller, J Lundgren.  (EuroSIDA oral ses. 4)

5. Design of safety reports from the EuroSIDA study. N Friis-Møller, O Kirk, JD Lundgren. (EuroSIDA poster ses.6)

The 1st IAS Conference o­n HIV Pathogenesis and Treatment, Buenos Aires, July 2001

1. Non-Hodgkin lymphoma (NHL) among HIV-infected patients in the era of highly active antiretroviral therapy (HAART). O Kirk, A Mocroft, S Barton, C Pedersen, P Skinhøj, V Miller, J Lundgren. (EuroSIDA 69)

2. Soluble urokinase plasminogen activator receptor (suPAR) – A potential marker for responsiveness to HAART? K Jensen, C Madsen, O Kirk, A Meyer, J Parner, J Lundgren, K Krogsgaard, J Eugen-Olsen. (Diverse 281)

8th European Conference o­n Clinical Aspects and Treatment of HIV-Infection, Athens, October 2001.

1. A randomised trial comparing continued indinavir vs switching to indinavir plus retonavir in HIV-patients having suppressed viral load with indinavir plus two nucleoside analogue reverse transcriptase inhibitors: The BEST study. J Gerstoft, J Mallolas, J Lundgren, G Faetkenheuer, A D´Arminio Monforte, F Antunes, P Reiss, JM Gatell. (BEST 240)

2. A phase IV randomised open-label, multicentre trial to evaluate safety and efficacy of indinavir/ritonavir (800/100 mg bid) vs. saquinavir /ritonavir (1000/100 mg bid) in adult HIV-1 infection: The MaxCmin1 trial. UB Dragsted.  (MaxCmin1 407)

3. Factors affecting incidence of and survival after CMV end-organ disease in patients with AIDS in Europe. I Yust, P Reiss, D Turner, O Kirk, C Katlama, A Mocroft, J van Lunzen, M Burke, A Chiesi, JD Lundgren. (EuroSIDA 521)

4. Cardiovascular risk-factors in HIV patients - association with antiretroviral therapy. The DAD Study. N Friis-Møller, P Reiss, O Kirk, A D'Arminio Monforte, M Rickenbach, R Thiebaut, C Pradier, L Morfeldt, G Calvo, M Law, G Bartsch, S De Witt, AN Phillips, JD Lundgren for the DAD Study Group. (DAD 408)


41st Interscience Conference o­n Antimicrobial agents and Chemotherapy, Chicago, December 2001.

1. Risks for cardiovascular disease (CVD) associated with antiretroviral therapy (ART). R Weber, N Friis-Møller, F Dabis, P Reiss, A D´Armino Monforte, G Calvo, C Pradier, L Morfeldt, M Law, A Phillips, JD Lundgren.  (DAD I-1326)

2. The DAD study: Data collection o­n adverse events of anti-HIV drugs. The DAD Study group (Oral pres. ses. 6)

3. The Stability of the viral load in subjects with virological failure who remain o­n the same HAART regimen: The EuroSIDA study. JD Lundgren, A Cozzi-Lepri, V Miller, B Ledergerber, S Vella, J Weber, JN Bruun, O Kirk, B Clotet, A. Phillips.  (EuroSIDA I-1915)

 2000

7th Conference o­n retroviruses and opportunistic infections, San Francisco Jan/Feb 2000

1. Association of viral load, CD4 cell count, and treatment with clinical progression in HIV-patients with very low CD4 cell counts: The EuroSIDA cohort. V Miller, A Mocroft, B Clotet, B Ledergerber, O Kirk, A D´Arminio Monforte, and J Lundgren. (EuroSIDA 454) abstract

2. Virological response to a second-line protease inhibitor (PI) regimen: Laboratory markers and choice of treatment. A Mocroft, AN Phillips, V Miller, J Gatell, J Van Lunzen, A Lazzarin and J Lundgren. (EuroSIDA 539)

3. EuroSIDA: Temporal Changes in response to HAART. JD Lundgren, O Kirk, G Panos, FD Goebel, A Blaxhult, AN Phillips, A Mocroft.
(EuroSIDA 757)

4. It is safe to discontinue secondary prophylaxis for PCP in HIV-infected patients with HAART: Results from eight prospective European cohorts. B Ledergerber, A Mocroft, P Reiss, HJ Furrer, O Kirk, V Miller, C Pradier, C Uberti-Foppa, A D´Arminio-Monforte, MM Schneider and JD Lundgren. (EuroSIDA LB5)


The XIII International AIDS Conference, Duban, July 2000.

1. Low body weight and type of protease inhibitor (PI) predict treatment-limiting adverse drug reactions (TLADR) among HIV-infected patients starting a PI regimen. O Kirk, J Gerstoft, C Pedersen, H Nielsen, N Obel, TL Katzenstein, L Mathiesen, JD Lundgren.  (Protease WePeB4283) abstract

2. The influence of Hepatitis C virus (HCV) o­n the prognosis of HIV-infected persons: The EuroSIDA study. V Soriano, O Kirk, F Antunes, M Johnson, A d´Arminio-Monforte, LS Teglbjorg, F-D Goebel, JD Lundgren.
(EuroSIDA ThOrB655)

3. Factors associated with starting HAART and pneumocytis carinii pneumonia (PCP) prophylaxis among HIV seroconverters enrolled in the EuroSIDA study. P Vanhems, O Kirk, A Mocroft.
(EuroSIDA TuPeC3372)

40th Interscience Conference o­n Antimicrobial Agents and Chemotherapy, Toronto, September 2000.

1. Ykl-40 is elevated in cerebrospinal fluid from patients with bacterial meningitis and is associated with outcome. C Østergaard, JS Sørensen, T Benfield, PA Price, JD Lundgren. (Diverse 428) abstract 

2. Clinical correlation of pneumocystis carinii internal transcribed spacer genotypes in AIDS- related P. carinii Pneumonia. J Helweg-Larsen, C Lee, S Jin, Y Hsueh, T Benfield, J Hansen, JD Lundgren, B Lundgren.
(Diverse 1318)

3. The change in risk of clinical progression after initiation of HAART: The EuroSIDA study. JD Lundgren, A Mocroft, JM Gatell, O Kirk, C Katlama, S Vella, ANPhillips. ( EuroSIDA 1905)


Fifth International Congress o­n Drug Therapy in HIV-infection, Glasgow, October 2000.

1. Viral load changed in response to antiretroviral therapy according to the baseline CD4 lymphocyte count and viral load. AN Phillips, S Staszewski, R Weber, O Kirk, P Francioli, V Miller, P Vernazza, J Lundgren and B Ledergerber.  (EuroSIDA PL3.4) abstract

2. The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study. S Jensen-Fangel, O Kirk, A Blaxhult, J Gerstoft, C Pedersen, FT Black, JD Lundgren and N Obel.  (EuroSIDA P69) abstract 

3. The effect of HAART o­n retinal and extraocular cytomegalovirus infection in patients with AIDS in Europe. I Yust, A Mocroft, D Turner, C Katlama, B Clotet, O Kirk, J Van Lunzen, P Reiss, M Burke, A Chiesi, J Lundgren.
(EuroSIDA P375)

4. Decreasing incidence of non-Hodgkin Lymphoma (NHL) in the era of HAART: The EuroSIDA Study. O Kirk, A Mocroft, F Antunes, C Pedersen, P Skinhøj, V Miller, A Lazzarin, JM Gatell, S Barton and JD Lundgren.
(EuroSIDA P404)

5. Admission to hospital in the HAART era: The EuroSIDA study. N Friis-Møller, O Kirk, A Mocroft, JN Bruun, A Johnson, R Colebunders, R Proenca, J Gonzalés-Lahoz, A D´Arminio Monforte and JD Lundgren.
(EuroSIDA P410)